Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cellectar Biosciences, Inc. (NASDAQ: CLRB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including registration statements, current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Cellectar’s late-stage clinical oncology programs, capital structure and risk factors.
Through forms such as Form S‑1 and S‑1/A, investors can review descriptions of the company’s Phospholipid Drug Conjugate (PDC) platform, its lead radiotherapeutic candidates iopofosine I 131, CLR 121125 (CLR 125) and CLR 121225 (CLR 225), and the clinical and preclinical data supporting these programs. These registration statements also outline unit offerings, warrant terms, use of proceeds and the impact of actions like the one‑for‑thirty reverse stock split.
Form 8‑K current reports document material events, including scientific advice from the European Medicines Agency’s Scientific Advice Working Party on a potential Conditional Marketing Authorization for iopofosine I 131 in Waldenstrom’s macroglobulinemia, warrant inducement transactions, reverse stock split implementation, and preliminary financial information. Earnings press releases furnished as exhibits to 8‑Ks provide narrative overviews of quarterly performance and corporate updates.
On Stock Titan, CLRB filings are supplemented with AI‑generated highlights that summarize key points from lengthy documents, helping users quickly identify information on clinical milestones, regulatory designations, financing transactions and changes to capital structure. Real‑time updates from EDGAR ensure that new Cellectar filings, including future 10‑K annual reports, 10‑Q quarterly reports and any Form 4 insider transaction disclosures, are incorporated as they become available, while the full text remains accessible for detailed review.
Cellectar Biosciences, Inc. (Nasdaq: CLRB) has filed a Form 8-K to disclose that its stockholders approved, and the board of directors has subsequently set, a one-for-thirty reverse stock split of the company’s common stock. The split will take effect at 12:01 a.m. ET on June 24, 2025 (the “Effective Time”).
At the Effective Time, every 30 shares of issued and outstanding common stock will be automatically combined into 1 share; fractional shares will be paid out in cash. The filing notes that the reverse split will proportionately adjust (i) the share reserves under all company equity-incentive plans, (ii) the share quantities and exercise or conversion prices of outstanding stock options and warrants, and (iii) the conversion ratios of any outstanding preferred stock, thereby keeping the aggregate economic value of each instrument unchanged.
The company attached a press release (Exhibit 99.1) titled “Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split” and an Inline XBRL cover page file (Exhibit 104). No other operational or financial data were provided in this filing.